Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy

Cover Page

Cite item

Full Text

Abstract

Background. The neutrophil to lymphocyte ratio (NLR) is a prognostic marker in various carcinomas, including breast cancer. The NLR reflects the balance of systemic immunity and is associated with survival in patients with solid tumors.

Aim. This study retrospectively evaluated the significance of the NLR and the absolute lymphocyte count in patients with breast cancer who received eribulin therapy.

Materials and methods. The prognostic significance of the NLR and the absolute lymphocyte count in 33 patients with metastatic breast cancer treated with eribulin in 2020–2021 was analyzed.

Results. The median follow-up time for patients was 9 [6; 15] months. Twenty-six of 33 (78.8 %) patients progressed. Seven of 33 (21.2 %) patients were censored due to therapy discontinuation, complete discontinuation after 1 course was required in 3 (9.1 %) patients and was associated with the development of hematological toxicity: 1 (3 %) case of a combination of grade 3 leucopenia and grade 3 thrombocytopenia, 2 (6 %) cases of grade 3 neutropenia. According to the analysis results, the NLR was a statistically significant risk factor for progression in patients on eribulin therapy, both without taking into account the influence of other factors (univariate model) and with the underlying influence of the absolute neutrophil count and the absolute lymphocyte count: hazard ratio (95 % confidence interval) was 1.21 [1.04; 1.41], p = 0.015 and 1.30 [1.07; 1.57], p = 0.008, respectively. There was no statistically significant effect of the absolute neutrophil count and the absolute lymphocyte count in both univariate and multivariate models. To illustrate the impact of SNL on the onset of progression, patients were divided into two subgroups based on median SNL: SNL˂ 2.46 and SNL ≥2.46. The median survival in patients with SNL ≥2.46 was 9 months, and in patients with SNL˂ 2.46 it was 15 months.

Conclusion. The results of the pilot study state the NLR is a potential prognostic marker of long-term treatment with eribulin for patients with metastatic breast cancer, and can be used in clinical practice. 

About the authors

A. V. Zyuzyukina

Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia;
Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky

Author for correspondence.
Email: alena-vz@mail.ru
ORCID iD: 0000-0002-6758-4800

1 Partizana Zheleznyaka St., Krasnoyarsk 660022;

161-ya Smolenskaya St., Krasnoyarsk 660133

Russian Federation

V. A. Komissarova

Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky

ORCID iD: 0000-0002-5862-1761

161-ya Smolenskaya St., Krasnoyarsk 660133

Russian Federation

N. O. Popova

Tomsk Cancer Research Institute

ORCID iD: 0000-0001-5294-778X

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

V. E. Goldberg

Tomsk Cancer Research Institute

ORCID iD: 0000-0003-4753-5283

5 Kooperativnyy Pereulok, Tomsk 634009

Russian Federation

R. A. Zukov

Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenetsky, Ministry of Health of Russia;
Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky

ORCID iD: 0000-0002-7210-3020

1 Partizana Zheleznyaka St., Krasnoyarsk 660022;

161-ya Smolenskaya St., Krasnoyarsk 660133

Russian Federation

References

  1. Cardoso F., Kataja V., Tjan-Heijnen V. Breast cancer. Essentials for Clinicians. ESMO Press, 2019.
  2. Pagani O., Senkus E., Wood W. et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102(7):456–63. doi: 10.1093/jnci/djq029
  3. Yardley D.A. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 2010;10(1):64–73. doi: 10.3816/CBC.2010.n.009
  4. Andreopoulou E., Sparano J.A. Chemotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer: an overview. Curr Breast Cancer Rep 2013;5(1):42–50. doi: 10.1007/s12609-012-0097-1
  5. Cortes J., Vahdat L., Blum J.L. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28(2):3922–8. doi: 10.1200/JCO.2009.25.8467
  6. Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in pre-clinical human breast cancer models. Cancer Sci 2014;105(10):1334–42. doi: 10.1111/cas.12488
  7. Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelialmesenchymal transition (EMT) to mesenchymal-epithelial tran-sition (MET) states. Br J Cancer 2014;110(6): 1497–505. doi: 10.1038/bjc.2014.80
  8. Azab B., Bhatt V.R., Phookan J. et al. Usefulness of the neutrophil-tolymphocyte ratio in predicting shortand long-term mortality in breast cancer patients. Ann Surg Oncol 2012;19(1):217–24. doi: 10.1245/s10434-011-1814-0
  9. Templeton A.J., McNamara M.G., Seruga B. et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and metaanalysis. J Natl Cancer Inst 2014;106(6). doi: 10.1093/jnci/dju124
  10. Koh C.H., Bhoo-Pathy N., Ng K.L. et al. Utility of pre-treatment neutrophillymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer 2015;113(1):150–8. doi: 10.1038/bjc.2015.183
  11. Watanabe J., Saito M., Horimoto Y. et al. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. Breast Cancer Res Treat 2020;181(1):211–20. doi: 10.1007/s10549-020-05626-1
  12. Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treat-ment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377(9769):914–23. doi: 10.1016/S0140-6736(11)60070-6
  13. Twelves C., Anthoney A., Savulsky C.I. et al. A phase 1b/2, open-label, doseescalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. Br J Cancer 2019;120(6):579–86. doi: 10.1038/s41416-018-0366-5
  14. Kashiwagi S., Asano Y., Goto W. et al. Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One 2017;12(2):e0170634. doi: 10.1371/journal.pone.0170634
  15. Miyoshi Y., Yoshimura Y ., Saito K. et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician‘s choicein the EMBRACE study. Breast Cancer 2020;27(4):706–15. doi: 10.1007/s12282-020-01067-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.